中国药物经济学2025，Vol.20Issue(7)：5-12,18,9.DOI:10.12010/j.issn.1673-5846.2025.07.001
五项血清标志物联合增强CT检测用于肺癌辅助诊断的卫生经济学评价
The Health Economic Evaluation of Five Serum Markers Combined with Enhanced CT for Lung Cancer Adjuvant Diagnosis
王哲海 1陈志军 2许青霞 3刘基巍 4汝昆 1明坚 5陈英耀5
作者信息
- 1. 山东省肿瘤医院肿瘤内科,济南 250117
- 2. 江西省肿瘤医院核医学科,南昌 330029
- 3. 河南省肿瘤医院检验科,郑州 450003
- 4. 大连医科大学附属第一医院肿瘤内科,辽宁 大连 116011
- 5. 国家卫生健康委员会卫生技术评估重点实验室(复旦大学),上海 200032
- 折叠
摘要
Abstract
Objective To evaluate the cost-effectiveness of the five serum markers combined with enhanced CT(hereinafter referred to as CT)for the adjuvant diagnosis of lung cancer.Methods A decision tree model was built to measure the cost,correct diagnosis rate,and quality-adjusted life-years of four adjuvant diagnostic strategies within a 1-year time horizon,adopting the perspective of Chinese health system.Incremental analysis was used to evaluate the cost-effectiveness of five serum markers combined CT compared with the other three diagnostic strategies.The robustness of the base case analysis results was verified by one-way sensitivity analysis and probabilistic sensitivity analysis.Results Compared with the other three diagnostic strategies,the five serum markers combined with CT could improve the correct diagnosis rate for the adjuvant diagnosis of lung cancer and bring higher QALYs.The incremental correct diagnosis rate compared to CT,the three serum markers combination with CT,and the four serum markers combination with CT is 13.82%,3.05%,and 1.39%,respectively,and the incremental QALYs are 0.005 5,0.001 1,and 0.000 3.The five serum markers combined with CT could bring cost saving,and the cost saving is ¥1 526.15,¥544.35,and ¥475.26 compared to the other three diagnostic strategies.Five serum markers combined with CT is the dominant choice in all comparisons.Conclusion The combination of five serum markers and CT can not only improve the health output of patients but also save costs.It is recommended that this group be retained and included in the standardized clinical pathway under the background of the policy on standardized examination and testing.关键词
血清标志物/肺肿瘤/辅助诊断/成本-效果分析Key words
Biomarkers/Lung neoplasms/Diagnosis/Cost-effectiveness analysis分类
医药卫生引用本文复制引用
王哲海,陈志军,许青霞,刘基巍,汝昆,明坚,陈英耀..五项血清标志物联合增强CT检测用于肺癌辅助诊断的卫生经济学评价[J].中国药物经济学,2025,20(7):5-12,18,9.
